| Ytd | -6.96% | |
| 1y | -6.96% |
| Open | 1.55 | Prev Close | 1.59 | Low | 1.42 | High | 1.57 | Mkt Cap | 177.67M |
| Vol | 8.77M | Avg Vol | 18.92M | EPS | -1.13 | P/E | N/A | Forward P/E | -0.55 |
| Beta | 0.63 | Short Ratio | 1.26 | Inst. Own | 35.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.73 | 200-d Avg | 0.90 | 1yr Est | 24.80 |
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the stand
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and